SUVOREXANT TAB,ORAL
Clinical Criteria Summary
Continuity of Care Inclusion Criteria
- Veteran is transitioning care from Department of Defense to VHA and the medication is determined by a VA prescriber using shared decision making to be safe and clinically appropriate, or is needed for dose tapering / slowly discontinuing therapy
Exclusion Criteria
- Narcolepsy and/or cataplexy
- Concomitant therapy with STRONG CYP3A4 inhibitors
- History of complex sleep behaviors
- Active substance use disorder
- Considered a high suicide risk
- Untreated sleep-related breathing disorder-obstructive or central sleep apnea syndrome or central alveolar hypoventilation syndrome
- Severe hepatic impairment (i.e., Child-Pugh C)
- Receiving other drugs to treat insomnia
Inclusion Criteria
- Prescribed and monitored by a VA / VA Community Care mental health or sleep provider or locally designated expert in insomnia
- Documented diagnosis of insomnia characterized by difficulties with sleep onset and/or sleep maintenance
- When available, cognitive behavioral therapy for insomnia (CBT-I) has been tried, via face to face, tele-mental health or non-VA care
- An adequate short-term trial of 2 formulary sedative hypnotics for the treatment of sleep onset and maintenance have been tried and failed to resolve symptoms or were not tolerated
- An adequate trial of daridorexant has been tried and failed or was not tolerated